0001193125-26-211889
SEC filingRevenue grew 2.7% YoY to $823.4M, but GAAP operating income fell 67.9% on foreign exchange headwinds and restructuring costs.
In Q1 2026, Bruker reported total revenue of $823.4 million, up 2.7% year-over-year from $801.4 million. Growth was primarily driven by foreign exchange tailwinds and recent acquisitions, particularly within the BSI CALID segment. However, on a constant-currency basis, revenue declined 1.8%, and organic revenue fell 4.4%, underscoring underlying demand weakness in academic and industrial markets. All geographic regions showed mixed trends: European revenue increased 12.8%, while North America was flat (-0.2%) and Asia Pacific fell 10.3%, led by China. GAAP gross profit declined 2.9% to $379.8 million, and gross margin contracted 270 basis points to 46.1%. This decline was attributed to foreign exchange headwinds from a weakening U.S. Dollar, lower revenue volume, and unfavorable revenue mix, which were only partially offset by cost savings initiatives. GAAP operating income dropped sharply by 67.9% to $10.2 million, driven by the same profit headwinds along with higher restructuring costs and long-lived asset impairment charges of $12.2 million. Non-GAAP operating margin also declined 250 basis points to 10.2%, with management citing the same fundamental pressures. Net income attributable to Bruker common shareholders fell 79.9% to $3.5 million, largely due to the new preferred stock dividend obligation of $10.9 million, which began in Q1 2026 following the September 2025 issuance of Series A Mandatory Convertible Preferred Stock.
BSI CALID was the standout segment, posting a 12.9% revenue increase to $316.3 million, fueled by the Tofwerk acquisition and volume growth in Optics and Security Detection. However, its GAAP operating margin slipped to 12.9% from 14.4%, reflecting input cost pressures and mix. BSI BioSpin revenue fell 5.0% to $197.5 million, driven by softer academic and government demand and the absence of a GHz-class NMR sale (one was sold in Q1 2025 vs. none in Q1 2026). Operating margin contracted 330 basis points to 8.1%. BSI NANO posted a 4.1% revenue decline to $246.0 million and swung to an operating loss of $(21.8) million, driven by weak industrial and academic markets and heavy restructuring/impairment charges, partially offset by semiconductor growth. BEST revenue grew 12.6% to $66.8 million, with operating margin holding relatively steady at 11.2%.
Management highlighted a cost savings initiative announced in August 2025 targeting $100–$120 million in annualized cost reductions by the end of 2026, already partially offsetting headwinds. However, the broader outlook remains cautious due to ongoing tariff uncertainty—including U.S. tariffs on German and Swiss imports, some of which have been struck down by the Supreme Court but remain subject to refund processes—and geopolitical risks. No formal forward guidance on revenue or earnings was provided, but management noted that tariff-related uncertainty has contributed to lower bookings and profitability and is expected to continue near term. Capital allocation priorities appear focused on deleveraging (full repayment of the 2024 term loan) and investing selectively in growth areas, while share repurchases have been paused after the 2023 program expired in May 2025.
As of March 31, 2026, Bruker's cash and cash equivalents dropped sharply to $133.4M from $298.8M at year-end 2025, driven by debt repayment and acquisition outflows. Total debt decreased by $197.8M to $1,671.3M, reflecting a CHF 179.1M term loan repayment and no new borrowings. Shareholders' equity remained stable at $2,467.0M. Inventory increased to $1,121.5M, with finished goods in-transit at $71.8M. Remaining performance obligations (RPO) rose to $2,707.8M, up 5.4% from $2,569.4M, with the majority expected to be recognized within 12 months.
No aggregate purchase commitments were disclosed. However, material legal settlements include: (i) $18.0M remaining to AbCellera (due Q2 2026) and (ii) $15.8M to 10x Genomics (paid in April 2026). The company also has a $10.9M put option liability for NovAliX (exercisable 2029-2034) and a $10.4M contingent consideration liability from acquisitions.
No share repurchases occurred in Q1 2026 as the 2023 Repurchase Program expired. Common dividends totaled $7.7M ($0.05 per share), unchanged from prior year. Preferred dividends on Series A Mandatory Convertible Preferred Stock were $10.9M (6.375% annual rate). Debt reduction was the primary capital allocation, with $181.3M repaid (net debt -$197.8M). Capital expenditures were $17.9M (2.2% of sales), down from $26.0M a year ago, with the largest spend in BSI CALID ($6.7M) and BSI NANO ($4.9M).
Four segments reported: BSI BioSpin ($197.5M, -5.0% YoY), BSI CALID ($316.3M, +12.9%), BSI NANO ($246.0M, -4.1%), and BEST ($63.6M, +11.8%). Operating margins were 14.6%, 19.8%, 5.9%, and 11.9%, respectively. Total segment operating income fell to $113.4M from $128.7M, impacted by $12.9M impairment charges in BSI NANO and restructuring costs. Geographically, revenue was led by Europe ex-Germany ($258.9M), United States ($221.9M), and Asia Pacific ex-China ($134.7M). China revenue declined 26.9% to $74.0M, reflecting ongoing macro headwinds.
Operating cash flow of $71.2M significantly exceeded net income of $15.7M, driven by $58.3M in depreciation and amortization and $21.4M in other non-cash items. Working capital was a $24.2M use of cash, primarily due to a $47.2M inventory buildup partially offset by higher payables. Capex of $24.2M (34% of CFO) was moderate. Free cash flow (CFO minus capex) of $47.0M covered dividends of $18.6M, leaving $28.4M for deleveraging. The company made a large debt repayment of $181.3M, contributing to a $204.9M financing outflow, and initiated $11.0M in preferred dividends. No share repurchases occurred in Q1 2026.
Inventory increased sharply by $47.2M, likely reflecting supply chain or demand anticipation. The $181.3M debt repayment was unusual, possibly opportunistic deleveraging. Cash and equivalents decreased by $165.5M, ending at $137.6M.